Scarica l'app Stockscreener
0.9968
0.33%
0.00015
Precedente Chiudi:
$0.9966
Aprire:
$0.999
Volume 24 ore:
194.29K
Relative Volume:
0.17
Capitalizzazione di mercato:
$108.18M
Reddito:
$4.35M
Utile/perdita netta:
$-45.53M
Rapporto P/E:
-0.9229
EPS:
-1.08
Flusso di cassa netto:
$-44.79M
1 W Prestazione:
-1.97%
1M Prestazione:
-12.29%
6M Prestazione:
-21.88%
1 anno Prestazione:
+26.57%
Intervallo 1D:
$0.9901
$1.03
Intervallo di 1 settimana:
$0.9502
$1.0496
Portata 52W:
$0.73
$1.80
Lucid Diagnostics Inc Stock (LUCD) Company Profile
Nome
Lucid Diagnostics Inc
Settore
Industria
Telefono
212 949 4319
Indirizzo
360 MADISON AVENUE, NEW YORK
Confronta LUCD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LUCD
Lucid Diagnostics Inc
|
0.9999 | 107.10M | 4.35M | -45.53M | -44.79M | -1.08 |
|
ABT
Abbott Laboratories
|
130.88 | 227.88B | 43.11B | 13.98B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.72 | 152.55B | 18.49B | 2.51B | 3.23B | 1.68 |
|
SYK
Stryker Corp
|
375.46 | 143.34B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.57 | 114.49B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.86 | 46.15B | 5.69B | 4.14B | 577.90M | 6.96 |
Lucid Diagnostics Inc Stock (LUCD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-12-27 | Iniziato | Ascendiant Capital Markets | Buy |
| 2021-11-08 | Iniziato | BTIG Research | Buy |
| 2021-11-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-11-08 | Iniziato | Needham | Buy |
Lucid Diagnostics Inc Borsa (LUCD) Ultime notizie
Why Lucid Diagnostics Inc. stock attracts strong analyst attentionDaily Growth Stock Pick Reports Show Bullish Signals - metal.it
Lucid Diagnostics to Participate in Upcoming Investor Conferences - Eastern Progress
Cancer Prevention Leader Lucid Diagnostics Headlines Two Major Healthcare Investment Conferences This Month - Stock Titan
Lucid Diagnostics Inc. Breakout Confirmed by Volume MetricsROI Boosting Trade Opportunity Calendar Published - beatles.ru
What institutional investors are buying Lucid Diagnostics Inc. stockFree Trading Strategy Suggestions - Jammu Links News
Does Lucid Diagnostics Inc. stock perform well during market downturnsInvest confidently with actionable market data - Jammu Links News
How strong is Lucid Diagnostics Inc. company’s balance sheetConsistent triple-digit returns - Jammu Links News
What are the technical indicators suggesting about Lucid Diagnostics Inc.Achieve consistent profits with expert advice - Jammu Links News
When is Lucid Diagnostics Inc. stock expected to show significant growthUnlock your portfolio’s full growth potential - Jammu Links News
Is Lucid Diagnostics Inc. a good long term investmentFree Stock Chart Pattern Guide - Jammu Links News
Should I hold or sell Lucid Diagnostics Inc. stock in 2025Outstanding capital growth - Jammu Links News
What are Lucid Diagnostics Inc. company’s key revenue driversRapid capital growth - Jammu Links News
Published on: 2025-08-03 06:14:38 - Jammu Links News
How does Lucid Diagnostics Inc. generate profit in a changing economyMaximize returns with smart investment plans - Jammu Links News
PAVmed gets 180-day extension to regain Nasdaq listing compliance - MSN
PAVmed CEO and CFO to Present Q2 2025 Results and Growth Strategy Update on August 14 - Stock Titan
Lucid Diagnostics to Host Business Update Conference Call and Webcast on August 13, 2025 - AInvest
Lucid Diagnostics Announces Business Update Conference Call on August 13, 2025 - AInvest
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025 - Barchart.com
Lucid nearing Medicare coverage for EsoGuard test, maintain at Buy: BTIG - MSN
Cancer Prevention Leader Lucid Diagnostics to Reveal Q2 2025 Financial Results and Growth Strategy - Stock Titan
What explains LUCD's volatile earnings in 2024? - AInvest
Lucid Diagnostics Awaits Medicare Coverage for EsoGuard Test: Analysts Project 245.48% Price Appreciation and 333.71% Upside Potential - AInvest
Lucid Diagnostics on Track for Medicare Coverage Boosts BTIG's Buy Rating to $2 Target - AInvest
Why did LUCD's Q4 earnings fall short of forecasts? - AInvest
How does Lucid Diagnostics Inc. compare to its industry peersStock Strategy Picks For 2025 - jammulinksnews.com
Lucid Diagnostics' Medicare Coverage Catalyst: A Strategic Inflection Point for Esophageal Cancer Prevention - AInvest
How many analysts rate Lucid Diagnostics Inc. as a “Buy”Achieve consistent profits with expert strategies - Jammu Links News
What is Lucid Diagnostics Inc. company’s growth strategyAchieve consistent profits with proven methods - Jammu Links News
Is Lucid Diagnostics Inc. a growth stock or a value stockInvest confidently with professional market insights - Jammu Links News
What are the latest earnings results for Lucid Diagnostics Inc.Extraordinary market timing - jammulinksnews.com
Lucid Diagnostics Inc. Earnings Report Breakdown: What Investors Should KnowFree Stock Market Insider Analysis - Newser
What is the dividend policy of Lucid Diagnostics Inc. stockDiscover the next big stock winners - Jammu Links News
Sectors Driving Future Growth for Lucid Diagnostics Inc. StockDaily Price Surge List - Newser
What drives Lucid Diagnostics Inc. stock priceHigh-yield growth strategies - PrintWeekIndia
What analysts say about Lucid Diagnostics Inc. stockFree Consultation - PrintWeekIndia
Lucid Diagnostics Inc. Stock Analysis and ForecastBreakthrough capital growth - Jammu Links News
Lucid Diagnostics Inc Azioni (LUCD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Lucid Diagnostics Inc Azioni (LUCD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Matheis Dennis | Director |
May 21 '25 |
Buy |
1.32 |
129,684 |
171,520 |
316,782 |
| Matheis Dennis | Director |
May 22 '25 |
Buy |
1.32 |
33,218 |
43,795 |
350,000 |
0.27%
0.72%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):